SavedAdd your journal

Journals / Solunum Hastalıkları / 2002 / Cilt: 13 - Sayı: 1

Fatal hepatitis due to antituberculosis therapy administered with fenitoin

Fenitoin ile birlikte antitüberküloz tedavi sonucu gelişen fetal hepatit

Naime TAŞDÖĞEN
Atike DEMİR
Aygün ÖZTOP
Emel ÇELİKTEN
Pages
45–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We decided to present this hepatitis case, which ended with death in a short period and probably developed as a consequence of the administration of hepatotoxic drug combination.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 57 years female, who has been under antiepileptic therapy for 30 years and whose liver function tests were found to be within normal limits, was recently diagnosed as tuberculosis pleurisy.
📊
Key Findings & Data:A combination of 4 antituberculosis drugs administered to her, but at the 3rd day of the therapy fulminant hepatitis was developed and the case died at 4th day.
💡
Conclusion & Impact:We decided to present this hepatitis case, which ended with death in a short period and probably developed as a consequence of the administration of hepatotoxic drug combination.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Fenitoin · Antikonvülzanlar · Antitüberküler ajanlar

Abstract

A 57 years female, who has been under antiepileptic therapy for 30 years and whose liver function tests were found to be within normal limits, was recently diagnosed as tuberculosis pleurisy. A combination of 4 antituberculosis drugs administered to her, but at the 3rd day of the therapy fulminant hepatitis was developed and the case died at 4th day. We decided to present this hepatitis case, which ended with death in a short period and probably developed as a consequence of the administration of hepatotoxic drug combination.

Özet

Otuz yıldır antiepileptik tedavi (fenitoin) gören ve karaciğer fonksiyon testleri normal sınırlarda seyreden 57 yaşındaki kadın olguda tüberküloz plörezi saptandı. Dörtlü antitüberküloz tedavi başlanan ve tedavinin 3. gününde fulminan hepatit gelişen olgu 4. günde eksitus oldu. Hepatotoksik ilaçların birlikte kullanımına bağlı olarak geliştiğini düşündüğümüz ve kısa sürede eksitusla sonuçlanan bu hepatit olgusunu sunmayı uygun bulduk.

🔖

Cite This Article

TAŞDÖĞEN, N., DEMİR, A., ÖZTOP, A., ÇELİKTEN, E. (2002). Fatal hepatitis due to antituberculosis therapy administered with fenitoin. Solunum Hastalıkları, Cilt: 13 - Sayı: 1, 45–48. https://ajindex.com/articles/318701

References (17)

  1. Singh J, Arora A, Garg PK et al. Antituberculosis treatment-induced hepatotoxicity: Role of predictive factors. Postgrad Med J 1995;71:359-62
  2. Ungo JR, Jones D, Ashkin D et al. Antituberculosis druginduced hepatotoxicity. The role of hepatitis C virus and human immunodeficiency virus. Am J Respir Crit Care Med l998;157(6 Pt 1):1871-6
  3. Durand F, Jebrak G, Pessayre D et al. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf l996;15:394-405
  4. Girotto L, Gjonovich A, Preciso G. Fulminant liver failure caused by antituberculosis drugs. Report of a clinical case. Minerva Anestesiol 2000;66:249-51
  5. Lammert F, Matern S. Hepatic diseases caused by drugs. Schweiz Rundsch Med Prax l997;86:1167-71
  6. Amacher DE. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol l998;27:119-30
  7. Erokhin VV, Panasek IA, Adamovich NV. Clinical-morphological criteria of drug-induced hepatitis in pulmonary tuberculosis patient. Probl Tuberk 1991;1:35-40
  8. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J l996;9:2026-30
  9. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol l996;22:211-4
  10. Devoto FM, Gonzalez C, Iannantuono R et al. Risk factors for hepatotoxicity induced by antituberculosis drugs. Acta Physiol Pharmacol Ther Latinoam l997;47: 197-202
  11. Pande JN, Singh SP, Khilnani GC et al. Risk factors for hepatotoxicity from antituberculosis drugs: A case-control study. Thorax l996;51:132-6
  12. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: An 11-year study. Tuber Lung Dis l996;77:335-40
  13. Smythe MA, Umstead GS. Phenytoin hepatotoxicity: A review of the literature. DICP l989;23:13-8
  14. Roy AK, Mahoney HC, Levine RA. Phenytoin-induced chronic hepatitis. Dig Dis Sci l993;38:740-3
  15. Self TH, Chrisman CR, Baciewicz AM, Bronze MS. Isoniazid drug and food interactions. Am J Med Sci l999; 317:304-11
  16. Ziegler HK, Sinazadeh M. Anticonvulsant drugs and liver damage (Author’s transl). J Neurol l975;208:207-20
  17. Bartelink AK, Lenders JW, van Herwaarden CL et al. Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy. Tubercle l983; 64:125-8.